



NOL[®] MONITORING

CONFIDENT PAIN MANAGEMENT FOR IMPROVED OUTCOMES

- ✓ CONTROL PAIN
- ✓ AVOID EXCESSIVE ANALGESIA
- ✓ ELIMINATE DOUBT

NOL[®] TECHNOLOGY

Accurate continuous and noninvasive nociception (pain response) monitoring for personalized analgesic treatment



PATIENTS VARY IN THEIR ANAESTHETIC REQUIREMENTS.¹

Without objective monitoring, how can you get it right?

In critical care, nociception and analgesia are assessed indirectly through changes in heart rate and blood pressure - which are not sufficiently sensitive or specific.^{2,3}

As a result, **insufficient or excessive analgesia may be administered**, potentially leading to postoperative pain, complications, delayed recovery, and associated costs.^{4,5,6}

THE ANALGESIA MANAGEMENT CHALLENGE



of surgical patients suffer from moderate to severe post-operative pain.⁵



of surgical patients suffer from opioid-related adverse effects leading to⁶:



extra days of hospitalization



extra cost per patient




increase in re-admissions

NOL REFLECTS THE PATIENT'S NOCICEPTIVE STATE

By analysing autonomous nervous system-related patterns, NOL reflects the impact of stimuli, and the effect of analgesic treatment.


The NOL index is a multiparameter composite of physiological signals based on artificial intelligence technology and a proprietary sensor platform.



NOL® VISUALIZES NOCICEPTION

Multiparametric physiological data is acquired from sensors, and the derived nociception pattern is displayed on the PMD-200™ monitor. This AI-based technology allows the clinician to tailor analgesia to meet the patient's needs.

- A** NOL trend **above 25** is indicative of nociceptive response.
- B** NOL **below 10** may indicate excessive analgesia.
- C** NOL **below 25** is indicative of good nociception-antinociception balance.



THE BENEFITS OF NOL-GUIDED ANALGESIA

- ✓ Smoother procedures and better outcomes^{2,7}
- ✓ Personalized opioid dosing^{2,7,8}
- ✓ Supporting opioid-sparing anaesthesia⁹
- ✓ Confirming effectiveness of multimodal and regional analgesia^{10,11}
- ✓ Safer analgesia in high-risk patients¹²

THE IMPACT OF NOL AS SHOWN IN CLINICAL STUDIES

33%

Less postoperative pain⁷

30%

Less intraoperative opioid use²

80%

Fewer intraoperative hypotensive events²

NOL values in response to incision could **predict postoperative pain scores**⁸

HOSPITAL COST SAVINGS



Within less than 1 year of purchase¹³



Reduce costs associated with postoperative patient care¹⁴

PMD-200™ MONITOR | PRODUCT SPECS

PMD-200™ Monitor

Dimensions	24 × 19.3 × 15cm (9.45 x 7.6 x 5.9in)
Weight	3.5 kg
MDD classification	Class IIa
Regulatory approvals	Europe, Canada, Australia, Israel, Brazil, South Africa, UAE
Interface	English, Danish, Dutch, Finnish, French, German, Italian, Norwegian, Portuguese, Romanian, Spanish, Swedish

Finger Probe

Reusable

Dimensions Finger Probe + Cable: 270cm (106.3in)

PVC free, Latex free, Biocompatible

Sensor

Single use only

PVC free, Latex free, Biocompatible

The NOL index provides clinicians with a valuable decision support tool to objectively assess and optimize analgesia.

REFERENCES

1. Barash, P. G. et al. (2017). Clinical Anesthesia, 8th Ed. Lippincott Williams & Wilkins (LWW).
2. Meijer, F. et al. (2019). Nociception-guided versus Standard Care during Remifentanyl-Propofol Anesthesia: A Randomized Controlled Trial. *Anesthesiology*, 130(5), 745-755.
3. Edry, R., Recea, V., Didust, Y. & Sessler, D. I. (2016). Intraoperative validation of the NOL Index, a non-invasive nociception monitor. *Anesthesiology*, 125, 193-203.
4. Gan, T.J. et al. (2014). Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. *Current Medical Research and Opinion*, 30:149-6.
5. Kehlet H et al., (2006), Persistent postsurgical pain: risk factors and prevention, *Lancet* 367(9522):1618-25.
6. Oderda G et al. (2013). Effect of Opioid-Related Adverse Events on Outcomes in Selected Surgical Patients. *J Pain Palliat Care Pharmacother*, 27:62-70.
7. Meijer, F. et al. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. *British Journal of Anaesthesia*, 125(6):1070-1078.
8. Ledowski, T., Schlueter, P. & Hall, N. (2021). Nociception level index: do intra-operative values allow the prediction of acute postoperative pain?. *J Clin Monit Comput*. <https://doi.org/10.1007/s10877-021-00654-8>
9. Coeckelenbergh, S. et al. (2021). Effect of dexmedetomidine on Nociception Level Index-guided remifentanyl antinociception. *European Journal of Anaesthesiology*. doi:1097/EJA.0000000000001402
10. NOL case report: Identifying Effectiveness of Suprascapular Nerve Block and Opioid Sparing with NOL. Medasense. Access at <https://medasense.com/case-reports>
11. NOL case report: Identifying Nerve Block Effectiveness and Analgesia Management. Medasense. Access at <https://medasense.com/case-reports>
12. NOL case report: NOL in High-Risk Anaesthesia. Medasense. Access at <https://medasense.com/case-reports>
13. Saunders R., Weissbrod R. (2020). Cost benefit of personalizing intraoperative pain management. ISPOR Virtual Conference, May 2020.
14. Coreva Scientific and Medasense Biometrics. (2021). NOL Monitoring & Postoperative Pain Management: Economic Value Narrative.



info@medasense.com | www.medasense.com